Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Thepot S, et al. Among authors: jourdan e. Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7. Leuk Res. 2014. PMID: 25449687 Clinical Trial.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. Among authors: jourdan e. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H; French AML Intergroup. Jourdan E, et al. Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15. Blood. 2013. PMID: 23321257 Free article. Clinical Trial.
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.
Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N. Boissel N, et al. Among authors: jourdan e. Haematologica. 2015 Jun;100(6):780-5. doi: 10.3324/haematol.2014.114884. Epub 2015 Feb 24. Haematologica. 2015. PMID: 25715404 Free PMC article. Clinical Trial.
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).
Duployez N, Micol JB, Boissel N, Petit A, Geffroy S, Bucci M, Lapillonne H, Renneville A, Leverger G, Ifrah N, Dombret H, Abdel-Wahab O, Jourdan E, Preudhomme C. Duployez N, et al. Among authors: jourdan e. Leuk Lymphoma. 2016;57(1):199-200. doi: 10.3109/10428194.2015.1037754. Epub 2015 May 15. Leuk Lymphoma. 2016. PMID: 25856206 No abstract available.
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, Ifrah N, Dombret H, Jourdan E, Preudhomme C, Boissel N; French AML Intergroup. Willekens C, et al. Among authors: jourdan e. Haematologica. 2016 Mar;101(3):328-35. doi: 10.3324/haematol.2015.131946. Epub 2015 Dec 3. Haematologica. 2016. PMID: 26635039 Free PMC article. Clinical Trial.
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group. Rousselot P, et al. Among authors: jourdan e. Blood. 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27. Blood. 2016. PMID: 27121472 Free PMC article.
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.
Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N. Pigneux A, et al. Among authors: jourdan e. J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24. J Clin Oncol. 2017. PMID: 28129526
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.
Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C; French Innovative Leukemia Organization. Pigneux A, et al. Among authors: jourdan e. J Clin Oncol. 2018 Nov 10;36(32):3203-3210. doi: 10.1200/JCO.2018.78.7366. Epub 2018 Sep 27. J Clin Oncol. 2018. PMID: 30260758
139 results